13Aug, 2016

KRAS Testing for Colorectal Cancers (CRC)

By: | Tags:

Colorectal cancer (CRC) remains the third leading cause of cancer-related deaths in the United States and nearly 50% of patients will experience metastases during their lives. Anti EGFR targeted therapy is used for treatment of metastatic colorectal cancer. Approximately 30-50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene. This mutated KRAS gene is predictive of resistance to EGFR therapies in advanced colorectal cancer. NCCN guidelines on colon cancer (Feb.2016) recommend that all patients with metastatic colorectal cancer should have tumor tissue genotyped for KRAS mutations.
READ MORE

13Aug, 2016

EGFR Testing for Advanced Non-Small Cell Lung Cancer (NSCLC)

By: | Tags:

NSCLC accounts for about 85% of lung cancers and includes predominantly adenocarcinomas and squamous cell carcinomas. In the United States, about 15% of patients with NSCLC have mutations in Epidermal Growth Factor Recepter (EGFR). Testing for EGFR mutations is performed to identify patients who may benefit from targeted therapy such as tyrosine kinase inhibitor (TKIs).Identification of EGFR mutations is now accepted as standard practice, supported by NCCN Clinical practice guidelines. The presence of EGFR mutations may confer an improved response to anti EGFR-targeted therapy and can prove to be beneficial […]
READ MORE

13Aug, 2016

BRAF Mutation Analysis in Colorectal Cancers and Melanomas

By: | Tags:

BRAF gene mutation testing is now considered critical in diagnosis, prognosis, treatment, and predicting patient outcome in response to targeted therapy for multiple cancer types. Mutations in BRAF have been reported in up to 60% of cutaneous melanomas and up to 18% of colorectal cancers. About 90% of these mutations are found to be V600E. Treatment with vemurafenib, a highly selective and potent inhibitor of BRAF V600E has shown promise in overall improvement and progression-free survival of patients with advanced melanoma with the V600E mutation. BRAF mutation testing has been […]
READ MORE